PPAR Research

PPAR Research / 2010 / Article
Special Issue

PPARs and Xenobiotic-Induced Adverse Effects: Relevance to Human Health

View this Special Issue

Erratum | Open Access

Volume 2010 |Article ID 627284 | https://doi.org/10.1155/2010/627284

Barbara D. Abbott, Carmen R. Wood, Andrew M. Watkins, Kaberi P. Das, Christopher S. Lau, "Erratum to “Peroxisome Proliferator-Activated Receptors Alpha, Beta, and Gamma mRNA and Protein Expression in Human Fetal Tissues”", PPAR Research, vol. 2010, Article ID 627284, 2 pages, 2010. https://doi.org/10.1155/2010/627284

Erratum to “Peroxisome Proliferator-Activated Receptors Alpha, Beta, and Gamma mRNA and Protein Expression in Human Fetal Tissues”

Received31 Dec 2010
Accepted31 Dec 2010
Published26 May 2011

In the above-mentioned paper, the expression of PPARγ was incorrectly determined based on the quantification of a 50 kD band on the Western blots. This band aligned with what was believed to be a positive control band in the U937 whole cell extract, a control reagent recommended by the supplier of the primary antibody, SC-7196 (Santa Cruz Biotechnologies, Santa Cruz, CA). Based on recent information described by Foreman et al. [1], it is clear that this band is not PPARγ but was a nonspecific immunoreactive protein detected by SC-7196. This nonspecific protein was abundantly detected by SC-7196 in U937 and COS-1 cells as well as across all human fetal protein samples. Immunoprecipitation of COS-1 cell lysate using agarose-conjugated SC-7196 resulted in a single band on a Coomassie Blue-stained gel. This band was subjected to digestion, peptide extraction, and sequence analysis using MALDI-MSMS, and the protein was identified as cytoplasmic actin with a decisive score (human SwissProt database, 60% protein coverage using the 15 highest scoring peptide groups and two lower scoring but acceptable peptides).

A specific band for PPARγ, (calculated molecular weight for human PPARγ1 = 54.55 kD) was identified on our Western blots by performing new experiments in which in vitro translated human PPARγ1 (provided by J. Peters, Pennsylvania State University) was compared with human fetal tissue lysates (Figure 1). These experiments also included COS-1 cell lysate as a negative control and U937 cell lysate. The Western blots of the fetal tissues were all reanalyzed using the ~55 kD band that aligned with the in vitro translated human PPARγ1. Based on this reanalysis, the expression of PPARγ protein shown in (c) of Figures  1–9 are replaced by Figure 2. The data summary described in Table  1 of the above-mentioned paper regarding the change in PPARγ protein expression with fetal age is replaced by Table 1.


TissueProtein change with age

ThymusNS
IntestineIncrease
SpleenDecrease
LiverIncrease
KidneyDecrease
LungDecrease
StomachNS
HeartDecrease
AdrenalDecrease

NS = no significant change with age.

The authors regret this unexpected error. The clarification of the recognition patterns of this primary antibody should be of value to investigators interested in detecting PPARγ protein.

References

  1. J. E. Foreman, J. M. Sorg, K. S. McGinnis et al., “Erratum: to Regulation of peroxisome proliferator-activated receptor-β/δ by the APC/β-CATENIN pathway and nonsteroidal antiinflammatory drugs,” Molecular Carcinogenesis, in press. View at: Publisher Site | Google Scholar

Copyright © 2010 Barbara D. Abbott et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


More related articles

 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder
Views537
Downloads365
Citations

Related articles

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.